Clinical Immunology Society

Tocilizumab

Summary

Tocilizumab is a humanized, monoclonal antibody directed at the IL-6 receptor (IL-6R) which blocks IL-6 mediated pro-inflammtory effects.

Tocilizumab has been evaluated in adults with Rheumatoid Arthritis and in children with systemic-onset Juvenile Idiopathic Arthritis. In these studies, patients treated with tocilizumab improved, and these are approved indications for administration in Japan.

The most common serious side-effects observed were severe bacterial infections.

Brand Name

Actemra

Other Names

MRA

Molecular Target

IL-6 receptor (IL-6R)

Molecular Structure

humanized, recombinant 

Licensed Indication, Major Target Diseases

Rheumatoid Arthritis (Japan), systemic-onset Juvenile Idiopathic Arthritis (Japan)

Manufacturer/Distributor

F. Hoffman-LaRoche & Chugai Pharmaceuticals

References

 Source  Link  Revision Date
 Access Date
Adachi Y, Yoshio-Hoshino N, Nishimoto N.  The blockade of IL-6 signaling in rational drug design.  Curr Pharm Des 14:1217-1224, 2008
http://www.ncbi.nlm.nih.gov/pubmed/18473869 2008  2008-May-28
Ohsugi Y, Kishimoto T.  The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.  Expert Opin Biol Ther 8:669-681, 2008
http://www.ncbi.nlm.nih.gov/pubmed/18407769
2008-May
2008-May-28
Actemra Manufacturer's Information, Chugai Pharmaceutical Co.
http://www.chugai-pharm.co.jp/genera...c_6458&lang=en
2008-05-22
2008-06-02
Tags
none

Files (0)

 
You must login to post a comment.

NO RELIANCE FOR MEDICAL DECISIONS

Information, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk.


Clinical Immunology Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Phone: 414/224-8095 | Fax: 414/272-6070
Email: info@clinimmsoc.org

© 2001-2008 Clinical Immunology Society  |  Web Site Disclaimer